Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022.
Related news for (FNCH)
- Finch Announces Reverse Stock Split of Common Stock
- Finch Announces Reverse Stock Split of Common Stock
- Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
- Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates